Skip to main content
SpringerLink
Log in

In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital

  • Concise Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Bacterial resistance among Gram-negative pathogens is a challenging clinical problem. Tigecycline has been developed specifically to overcome resistance. The aim of this study was to assess the in vitro activity of tigecycline against ESBL-producing Escherichia coli, ESBL-producing Klebsiella spp., and multidrug-resistant Enterobacter spp. Between May 2007 and March 2008, 26 strains of ESBL-producing Escherichia coli, 10 strains of ESBL-producing Klebsiella spp., and 27 strains of multidrug-resistant Enterobacter spp. were isolated consecutively from inpatients with a documented infection in which the collected isolate was identified as the probable causative organism. The in vitro susceptibility against tigecycline was measured by the E-test method. MIC50 values were 1 µg/ml, 2 µg/ml, and 3 µg/ml respectively. MIC90 values were respectively 1.5 µg/ml, 4 µg/ml, and 12 µg/ml. Nonsusceptibility rates of 35%, 100%, and 96% respectively were found using EUCAST breakpoints. Despite the limited number of strains tested, our in vitro data suggest that tigecycline is unsuitable for the treatment of infections with multidrug-resistant Enterobacteriaceae in our setting. Therefore, we suggest that larger multicenter studies should be conducted to reconsider the value of tigecycline for the treatment of infections with multidrug-resistant, Gram-negative bacteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gaynes R, Edwards JR (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41:848–854 doi:10.1086/432803

    Article  PubMed  Google Scholar 

  2. Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36:11–23 doi:10.1086/344654

    Article  Google Scholar 

  3. Livermore DM (2004) The need for new antibiotics. Clin Microbiol Infect 10:1–9 doi:10.1111/j.1465–0691.2004.1004.x

    Article  PubMed  Google Scholar 

  4. Stein GE, Craig WA (2006) Tigecycline: a critical analysis. Clin Infect Dis 43:518–524 doi:10.1086/505494

    Article  PubMed  CAS  Google Scholar 

  5. Hawkey P, Finch R (2007) Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 13:354–362 doi:10.1111/j.1469–0691.2006.01621.x

    Article  PubMed  CAS  Google Scholar 

  6. Noskin GA (2005) Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41:303–314 doi:10.1086/431672

    Article  Google Scholar 

  7. Pankey GA (2005) Tigecycline. J Antimicrob Chemother 56:470–480 doi:10.1093/jac/dki248

    Article  PubMed  CAS  Google Scholar 

  8. Kiratisin P, Tiengrim S, Yungyuen T et al (2006) In vitro activity of colistin and tigecycline against extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated from patients in Siriraj hospital. J Infect Dis Antimicrob Agents 23:21–24

    Google Scholar 

  9. Brown SD, Traczewski MM (2007) Comparative in vivo antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 45:2173–2179 doi:10.1128/JCM.02351–06

    Article  PubMed  CAS  Google Scholar 

  10. Wayne PA (2005) Clinical and Laboratory Standards Institute (CLSI)/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; fifteenth informational supplement, (M100-S15). CLSI 25

  11. Pillar CM, Draghi DC, Dowzicky MJ et al (2008) In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and E-test. J Clin Microbiol. Available via http://jcm.asm.org/cgi/reprint/JCM.00637-08v1 Accessed 12 August 2008

  12. Bolmström A, Karlsson A, Engelhardt A et al (2007) Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 45:2474–2479 doi:10.1128/JCM.00089–07

    Article  PubMed  Google Scholar 

  13. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee (2006) EUCAST technical note on tigecycline. Clin Microbiol Infect 11:1147–1149

    Article  Google Scholar 

  14. Morosini MI, Garcia-Castillo M, Coque TM et al (2006) Antibiotic coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 50:2695–2699 doi:10.1128/AAC.00155–06

    Article  PubMed  CAS  Google Scholar 

  15. Rodloff AC, Leclercq R, Debbia EA et al (2008) Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 4:307–314 doi:10.1111/j.1469–0691.2007.01943.x

    Article  Google Scholar 

  16. Hope R, Warner M, Potz NA et al (2006) Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from South-East England. J Antimicrob Chemother 58:1312–1314 doi:10.1093/jac/dkl414

    Article  PubMed  CAS  Google Scholar 

  17. Glupczynski Y, Berhin H, Rodriguez-Villalobos H, Struelens M, Jans B, The Belgian Infection Society (2007) Epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae in Belgium: preliminary results of a national multicentre survey in 2006. In: Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases. Abstract no. P-1355

  18. Dean CR, Visalli MA, Projan SJ et al (2003) Efflux-mediatec resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47:972–978 doi:10.1128/AAC.47.3.972–978.2003

    Article  PubMed  CAS  Google Scholar 

  19. Visalli MA, Murphy E, Projan SJ et al (2003) AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 47:665–669 doi:10.1128/AAC.47.2.665–669.2003

    Article  PubMed  CAS  Google Scholar 

  20. Ruzin A, Visalli MA, Keeney D et al (2005) Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49:1017–1022 doi:10.1128/AAC.49.3.1017–1022.2005

    Article  PubMed  CAS  Google Scholar 

  21. Komatsu T, Ohta M, Kido N (1990) Molecular characterization of an Enterobacter cloacae gene (romA) which pleiotropically inhibits the expression of Escherichia coli outer membrane proteins. J Bacteriol 172:4082–4089

    PubMed  CAS  Google Scholar 

  22. Babinchak T, Ellis-Grosse E, Dartois N et al (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41:354–367 doi:10.1086/431676

    Article  Google Scholar 

  23. Ellis-Grosse EJ, Babinchak T, Dartois N et al (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41:341–353 doi:10.1086/431675

    Article  Google Scholar 

  24. Anthony KA, Fishman NO, Linkin DR et al (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46:567–570 doi:10.1086/526775

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Microbiology, GZA Hospitals, Antwerp, Belgium

    R. Naesens, J. P. Ursi, J. Van Schaeren & A. Jeurissen

  2. Laboratory of Microbiology, GZA Sint-Augustinus, Oosterveldlaan 24, 2610, Wilrijk, Belgium

    A. Jeurissen

Authors
  1. R. Naesens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Ursi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Van Schaeren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Jeurissen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Jeurissen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naesens, R., Ursi, J.P., Van Schaeren, J. et al. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital. Eur J Clin Microbiol Infect Dis 28, 381–384 (2009). https://doi.org/10.1007/s10096-008-0629-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0629-9

Keywords

Search

Navigation